Table 2.
PASS-predicted antidiabetic activities of stevioside.
| Pa | Pi | Activity | |
|---|---|---|---|
| 1 | 0.799 | 0.013 | Beta-adrenergic receptor kinase inhibitor |
| 2 | 0.799 | 0.013 | G-protein-coupled receptor kinase inhibitor |
| 3 | 0.786 | 0.005 | Antidiabetic |
| 4 | 0.764 | 0.001 | Alpha glucosidase inhibitor |
| 5 | 0.721 | 0.005 | Antidiabetic (type 2) |
| 6 | 0.718 | 0.007 | Cholesterol antagonist |
| 7 | 0.637 | 0.009 | Beta glucuronidase inhibitor |
| 8 | 0.630 | 0.021 | Glucan endo-1.3-beta-D-glucosidase inhibitor |
| 9 | 0.575 | 0.004 | Nitric oxide antagonist |
| 10 | 0.498 | 0.007 | Antioxidant |